The Uromigos

Episode 453: ESMO 2025 - IMvigor011 20.10.2025 37:27 ↓

Alex Wyatt joins us to discuss Tom's IMvigor011 data and the field of ctDNA

Episode 452: ESMO 2025 - DV+ toripalimab in bladder cancer 19.10.2025 42:51 ↓

Matt Galsky discusses the exciting Presidential session data from the Chinese phase 3 of DV+ toripalimab in advanced urothelial cancer.

Episode 451: ESMO 2025 - PSMAddition 19.10.2025 30:31 ↓

Scott Tagawa discusses his ESMO Presidential presentation on Lu-PSMA-617 in patients with mHSPC

Episode 450: ESMO 2025 - CAPITELLO 19.10.2025 21:35 ↓

Elena Castro describes the CAPITELLLO prostate cancer trial and her analysis from ESMO 2025

Episode 449: ESMO 2025 - ENZARAD 19.10.2025 28:00 ↓

Paul Nguyen and Chris Sweeney double team the ENZARAD data and put it into context with other data including STAMPEDE

Episode 448: Neoadjuvant EV/Pembro in Cis-ineligible MIBC 18.10.2025 46:21 ↓

Christof Vulsteke joins Brian and Tom to discuss his practice-changing data on neoadjuvant EVP in MIBC. More applause!!

Episode 447: ESMO 2025 - RAMPART 18.10.2025 36:41 ↓

James Larkin joins to discuss adjuvant durva/treme vs observation in high risk resected RCC

Episode 446: ESMO 2025 - OPTIC and front-line RCC triplets 18.10.2025 36:20 ↓

Cristina Rodriguez joins us to discuss her data on front-line triplets, and we also discuss the prospective RNAseq-based biomarker OPTIC study

Episode 445: ESMO 2025 - Systemic Checkpoint Inhibition plus BCG in NMIBC (POTOMAC and ALBAN) 17.10.2025 36:54 ↓

Brad McGregor joins us on the heels of his #ESMO25 discussion of these important data in the NMIBC landscape.

Episode 444: ESMO 2025 Preview - Prostate and Renal Cancer 08.10.2025 41:58 ↓

Silke joins us to discuss some important data being presented in prostate cancer. Brian and Tom also cover the RCC data at ESMO 2025

Episode 443: ESMO 2025 Bladder Cancer Preview 02.10.2025 32:09 ↓

Tom and Brian preview the practice-changing bladder cancer data to be presented at ESMO 2025 in Berlin

Episode 441: The History of IO in Urothelial Cancer - Part 2 29.09.2025 33:16 ↓

Jonathan Rosenberg returns to finish this two-part series on IO drug development in urothelial cancer

Episode 440: The History of IO in Urothelial Cancer - Part 1 22.09.2025 45:39 ↓

Jonathan Rosenberg joins in this 2-part series on the history of IO-based therapy in Urothelial Cancer

Episode 439: Transcriptome Expression and Treatment Sensitivity in Prostate Cancer 15.09.2025 41:24 ↓

Gert Attard joins the show to discuss his recent Cell publication looking at tumor transcriptome-wide expression classifiers in advanced prostate cancer.

Episode 438: The History of Testis Cancer Treatment 08.09.2025 39:22 ↓

Christian Kollmannsberger joins us to walk through decades of advances in advanced testis cancer.

Episode 436: The History of IO in RCC - Part 2 25.08.2025 36:29 ↓

We continue our conversation with Mike Atkins and David McDermott, discussing IO-based combination therapy in RCC.

Episode 435: The History of IO in RCC - Part 1 18.08.2025 27:52 ↓

The fathers of IO therapy in RCC - Michael Atkins and David McDermott - join us to take a tour through IO development in RCC over the last 20 years.

Episode 434: IMPACT series - A Walk Through the History of VEGF TKI Development in RCC 04.08.2025 48:51 ↓

Danny Heng joins to tour through VEGF TKI drug development from sorafenib to tivozanib and everything in between.

Episode 432: ASCO 2025 Rapid Oral Session RCC/Bladder Recap 21.07.2025 27:49 ↓

Karie Runcie, MD joins us after chairing the ASCO 2025 rapid oral session to discuss the rcc/bladder presentations.

Episode 431: IMPACT series - Axel Bex on Impactful RCC Clinical Trials 14.07.2025 43:59 ↓

Axel Bex joins the show to discuss trials that he thinks have impacted RCC. We also discuss consolidative approaches, neoadjuvant trials and what can impact an academic career.

Episode 430: Structured Exercise Improves DFS/OS after Adjuvant Therapy in Colorectal Cancer - Does This Apply to GU Cancers? 07.07.2025 45:46 ↓

Chris Booth joins the show to discuss his recent NEJM paper that demonstrated significant DFS and OS improvements with a structured exercise program after adjuvant chemo in colorectal cancer. We discuss implications for GU and other malignancies.

Episode 428: ASCO 2025 Recap 16.06.2025 54:20 ↓

Brian, Tom and Silke discuss their highlights form ASCO 2025

Episode 427: Emerging Data in Non-muscle Invasive Bladder Cancer (NMIBC) 13.06.2025 40:27 ↓

Josh Meeks joins us to give stellar overview of the emerging data in this space. We also discuss the recent ODAC ruling for lower risk patients.

Episode 426 - ASCO 2025: AMPLITUDE Phase 3 of PARPi in mHSPC 06.06.2025 37:22 ↓

Gert Attard joins us to discuss this practice-changing data and the highlight of ASCO 2025

Episode 425: ASCO 2025 - AI-enabled selection of patients for benefit of ADT + ARPI 04.06.2025 19:39 ↓

Nick James discusses intriguing data from STAMPEDE to us AI to analyze pathology slides to predict benefit from ADT + abiraterone